Hims & HERS 35 % shares, where Novo Nordisk pulls the partnership plug

Novo Nordisk has ended a cooperation agreement with Hims & Hers, accusing the healthcare company from “failure to adhere to the law” regarding sales of overweight drugs.

With the launch of the coalition only in April, the Danish pharmaceutical maker sets a quick end as it was one of the shortest collaborators seen in the pharmaceutical industry.

The loss of Novo’s participation has lost the investor’s confidence greatly in Hims & Hers, as the shares in the end fell by 35 % in the market on June 23.

HIMS & HERS revenues have risen on the back of the Betbad -1 Bulk -1 sales (GLP -1RA). Complex medications are specially made and non -brands that contain the same active ingredient as the market is marketed.

A commercial shortage of medication is one of the criteria that allows the production of a boat, according to the US Food and Drug Administration (FDA). Hims & Hers was one of Many healthcare companies from the distance of the advancement of vehicle drugs that have flourished During this time.

Novo Nordisk has made a partnership with Hims & HERS to submit the GLP-1R-1RA Wegovy (Semaglutide) at a reduced price on the Hims & HERS platform, which was distributed via the Novocare pharmacy on the Internet in Pharma. This step was a COY strategy to get lost market revenues to increase the use of complex medications, with revenues It reduced its expectations 2025 Because of the opposite winds from the health care sector.

The FDA (FDA) has announced that the Wegov deficiency has ended in April, however, indicating a boost for the prospects of the Novo Nordisk Market. The agency has imposed that the facilities of external sources – which include HIMS & HERS – stopped complex production by May 22. The efforts made by a commercial body to use external sources to prevent this It did not succeed.

“Over one month of cooperation, HIMS & HERS Health failed to adhere to the law, which prohibits mass sales of the drugs that are under the guise of the wrong” allocation “and the spread of deceptive marketing that endangers the patient’s safety,” Novo Nordsk said in a statement.

Andrew Dodom, CEO of HIMS & HERS, said that Novo Nordsek is “misleading the audience.”

In a publication x“We refuse to be included in the demands of any anti -competition drug company that violates independent decisions for service providers and limit the patient’s choice,” Dodom said.

Since the FDA announced the final dates in April, Hims & Hers has been steadfast in maintaining that it will continue to provide compound drugs. Like healthcare companies from other dimensions such as Moci Health, it takes advantage of the legislative corridor that allows the sewing of the dose and drafting. The “dedicated” treatment approach, as it is believed, allows a constant sale of the GLP-1RAS compound.